New Study Reviews Safety of Peptides in Sports Medicine

A comprehensive new study published in Sports Medicine has examined the safety and efficacy landscape of peptide therapies used for musculoskeletal injuries and athletic performance enhancement. The research by Mendias and Awan provides crucial insights into both FDA-approved and unregulated peptides, highlighting significant gaps in human safety data for many compounds being marketed directly to patients.

What This Study Found

The researchers conducted a narrative review examining prominent peptides including AOD-9604, BPC-157, CJC-1295, FS-344, GHK-Cu, ipamorelin, MOTS-C, sermorelin, SS-31, tesamorelin, thymosin beta-4, and TB-500. The study suggests a concerning disparity between approved peptide drugs that have undergone rigorous safety testing and a "gray market" of unapproved compounds operating with limited regulatory oversight.

While the study found that many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, researchers noted that rigorous human safety data are scarce for most compounds. This gap between promising preclinical results and validated human studies represents a significant concern for patient safety.

The authors also examined the role of placebo effects in perceived peptide efficacy, particularly noting how social media amplifies these psychological benefits. The study suggests that patients may attribute improvements to peptide treatments that could be explained by natural healing processes or placebo responses.

Clinical Significance

This research highlights several critical points for healthcare providers and patients considering peptide therapies. The study found that while numerous peptide drugs have completed the FDA's rigorous approval process with established safety and efficacy profiles, many patients are accessing unapproved alternatives through online vendors or compounding pharmacies.

Researchers noted that the pharmacological properties of peptides—as compounds that bridge the gap between small-molecule drugs and large proteins—make them attractive therapeutic options. However, the study suggests that the potential for serious harm to patients exists when using compounds without adequate safety data.

The clinical significance extends beyond individual patient safety to broader healthcare system concerns. The study indicates that patient demand for accelerated injury recovery and performance enhancement is driving usage of these compounds, often without proper medical supervision or understanding of potential risks.

Current Access and Compliance Context

The study reveals a complex regulatory landscape where approved peptides like tesamorelin (Egrifta) exist alongside numerous unregulated compounds. Researchers found that this parallel market operates largely outside traditional regulatory oversight, creating challenges for both patients and healthcare providers.

The authors noted that many peptides are being marketed direct-to-consumer through various channels, including online platforms and specialized clinics. The study suggests this direct-access model bypasses traditional medical gatekeeping mechanisms designed to ensure appropriate use and monitoring.

From a compliance perspective, the research indicates that healthcare providers need better frameworks to discuss these therapies with patients. The study found that evidence-based discussions about peptide therapies require understanding both the regulatory status and the actual scientific evidence supporting each compound's use.

What Patients Should Know

Based on this comprehensive review, patients considering peptide therapies should understand several key points. The study suggests that not all peptides have equivalent safety profiles or regulatory status. FDA-approved peptides have undergone extensive testing for both safety and efficacy, while unapproved compounds may lack crucial human safety data.

Researchers found that patients should be aware of the significant placebo effects associated with peptide treatments. The study indicates that social media and marketing can amplify expectations, potentially leading to perceived benefits that aren't directly attributable to the peptide itself.

The authors emphasize that patients should discuss peptide therapies with qualified healthcare providers who can evaluate individual risk factors and treatment goals. The study suggests that alternative treatments with more established safety profiles may be appropriate for many musculoskeletal conditions.

Patients should also understand that purchasing peptides from unregulated sources carries additional risks related to product purity, potency, and contamination. The study found that quality control standards for unapproved peptides vary significantly across suppliers.

Conclusion

This important study provides a comprehensive framework for understanding the current state of peptide therapy in sports medicine. While researchers found promising potential for many peptides in animal studies, the lack of rigorous human safety data for most unapproved compounds represents a significant concern.

The research underscores the importance of working with qualified healthcare providers who understand both the therapeutic potential and safety considerations of peptide therapies. For patients interested in exploring peptide treatments, consulting with a knowledgeable practitioner is essential for making informed decisions about these powerful therapeutic compounds.

To find a qualified healthcare provider experienced in peptide therapy, visit peptideassociation.org/find-a-doctor.

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new treatment regimen. Individual results may vary, and peptide therapies may not be appropriate for all patients.

Citation: Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026 Apr. PMID: 41966639. DOI: 10.1007/s40279-026-02437-0.